Amphastar Pharma’s generic Adrenalin OK’d in U.S

The FDA approves Amphastar Pharmaceuticals’ (NASDAQ:AMPH) marketing application for emergency allergic reaction med Epinephrine Injection, USP 30 mg/30mL (1 mg/mL) Multiple Dose Vial, a generic version of Adrenalin^® (Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial) distributed in the United States by Par Pharmaceutical, Inc.

Market launch will commence in 2-3 months.

Per IQVIA, the U.S. market is ~$131M.

https://seekingalpha.com/news/3564515-amphastar-pharmas-generic-adrenalin-okd-in-u-s